Marlon R. Veldwijk

ORCID: 0000-0002-6821-3489
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Virus-based gene therapy research
  • Effects of Radiation Exposure
  • RNA Interference and Gene Delivery
  • Advanced Radiotherapy Techniques
  • Radiation Therapy and Dosimetry
  • CAR-T cell therapy research
  • Breast Cancer Treatment Studies
  • Hematopoietic Stem Cell Transplantation
  • Cancer Research and Treatments
  • Cancer Immunotherapy and Biomarkers
  • Neutropenia and Cancer Infections
  • Chronic Myeloid Leukemia Treatments
  • PARP inhibition in cancer therapy
  • DNA Repair Mechanisms
  • Viral Infectious Diseases and Gene Expression in Insects
  • Prostate Cancer Diagnosis and Treatment
  • Molecular Biology Techniques and Applications
  • Multiple Myeloma Research and Treatments
  • Cancer, Stress, Anesthesia, and Immune Response
  • Glioma Diagnosis and Treatment
  • Lung Cancer Diagnosis and Treatment
  • Chemokine receptors and signaling
  • Head and Neck Cancer Studies
  • BRCA gene mutations in cancer
  • Lung Cancer Treatments and Mutations

University Medical Centre Mannheim
2015-2024

Heidelberg University
2015-2024

University Hospital Heidelberg
2015-2024

Universitätsklinik für Strahlentherapie
2024

German Cancer Research Center
2000-2015

Heidelberg University
1998-2011

University of Mannheim
2006

Leiden University
1997

Cancer cells generally generate higher amounts of reactive oxygen species than normal cells. On the basis this difference, prodrugs have been developed (e.g., hydroxyferrocifen), which remain inactive in cells, but become activated cancer In work we describe novel aminoferrocene-based prodrugs, which, contrast to hydroxyferrocifen, after activation form not only quinone methides (QMs), also catalysts (iron or ferrocenium ions). The released products act a concerted fashion. particular, QMs...

10.1021/jm2014937 article EN Journal of Medicinal Chemistry 2011-12-19
Petra Seibold Adam Webb Miguel E. Aguado‐Barrera D. Azria C. Bourgier and 95 more Muriel Brengues Erik Briers Renée Bultijnck Patricia Calvo Ana Carballo Ananya Choudhury A. Cicchetti Johannes Claßen E. Delmastro Alison M. Dunning Rebecca M. Elliott Laura Fachal Marie‐Pierre Farcy‐Jacquet P. Gabriele E. Garibaldi Antonio Gómez‐Caamaño Sara Gutiérrez‐Enríquez Daniel S. Higginson Kerstie Johnson Ramón Lobato-Busto Meritxell Mollà Anusha Müller Debbie Payne Paula Peleteiro Giselle Post T. Rancati Tim Rattay Victoria Reyes Barry S. Rosenstein Dirk De Ruysscher Maria Carmen De Santis Jörg Schäfer Thomas Schnabel Elena Sperk R.P. Symonds Hilary Stobart Begoña Taboada‐Valladares Chris J. Talbot R. Valdagni Ana Vega Liv Veldeman Tim Ward Christian Weißenberger Catharine West Jenny Chang‐Claude Yolande Lievens M. Van Eijkeren Katrien Vandecasteele Elhaseen Elhamin Piet Ost Valérie Fonteyne Martijn Swimberghe Pieter Deseyne Wilfried De Neve Fréderic Duprez Marcus Mareel Chris Monten Annick Van Greveling Tom Vercauteren Leen Paelinck Gilles Defraene Rita Aerts Soumia Arredouani Maarten Lambrecht Ben Vanneste Roxana Draghici Frank A. Giordano Carsten Herskind Marlon R. Veldwijk Irmgard Helmbold Ulrich Giesche Petra Stegmaier Christian Weiß Thomas Blaschke Burkhard Neu Laura Lozza B. Avuzzi S. Morlino Claudia Sangalli Marzia Franceschini Belina Rodriguez-Lage Juan Fernández‐Tajes Olivia Fuentes-Ríos Isabel Domínguez-Rios Irene Fajardo-Paneque Paloma Sosa‐Fajardo Laura Torrado-Moya Mónica Ramos-Albiac Alexandra Giraldo M. Altabas Bibiana Piqué-Leiva David García-Relancio Alejandro Seoane-Ramallo Samuel Lavers Simon K. Wright

REQUITE aimed to establish a resource for multi-national validation of models and biomarkers that predict risk late toxicity following radiotherapy. The purpose this article is provide summary descriptive data.

10.1016/j.radonc.2019.04.034 article EN cc-by-nc-nd Radiotherapy and Oncology 2019-05-27

Despite the clinical application of adeno-associated virus (AAV) gene therapy, titration viral stocks has not yet been standardized. This complicates comparison between laboratories. Functional titering AAV is time-consuming, requires manipulation hazardous material, and often a high degree variability. We established an optimized real-time quantitative polymerase chain reaction (RQ-PCR) assay to determine titers compared it with functional green fluorescent protein (GFP)-based method. With...

10.1006/mthe.2002.0659 article EN cc-by-nc-nd Molecular Therapy 2002-08-01

Abstract Radiotherapy is a fundamental part of cancer treatment but its use limited by the onset late adverse effects in normal tissue, especially radiation-induced fibrosis. Since molecular causes for fibrosis are largely unknown, we analyse if epigenetic regulation might explain inter-individual differences risk. DNA methylation profiling dermal fibroblasts obtained from breast patients prior to irradiation identifies associated with One region characterized as differentially methylated...

10.1038/ncomms10893 article EN cc-by Nature Communications 2016-03-11

The purpose of this study was to construct and characterize iron oxide nanoparticles (IONPCO) for intracellular delivery the anthracycline doxorubicin (DOX; IONPDOX) in order induce tumor cell inactivation. More than 80% loaded drug released from IONPDOX within 24 h (100% at 70 h). Efficient internalization IONPCO HeLa cells occurred through pino- endocytosis, with both IONP accumulating a perinuclear pattern. were biocompatible maximum 27.9% ± 6.1% reduction proliferation 96 after treatment...

10.1038/s41598-020-67207-y article EN cc-by Scientific Reports 2020-06-29

Despite Imatinib's remarkable success in chronic myelogenous leukemia treatment, monotherapy frequently causes resistance, underlining the rationale for combination chemotherapy. A potential approach would be interrupting SDF-1/CXCR4 axis using selective CXCR4 antagonist Plerixafor (previously AMD3100), as this has been reported to provide survival-enhancing effects myeloid progenitor cells. By efficient blocking CXCR4(+)/BCR-ABL(+) cell line BV-173, plerixafor (1-100 muM) significantly...

10.1080/10428190903150847 article EN Leukemia & lymphoma/Leukemia and lymphoma 2009-01-01

Abstract One of the challenges radiation oncology in era personalized medicine is identification biomarkers associated with individual radiosensitivity. The aim research was to evaluate possible clinical value associations between clinical, physical, and biological factors, risk for development acute radiotoxicity patients prostate cancer. study involved forty four treated three-dimensional conformal radiotherapy. concentrations IL-1β, IL-2, IL-6, IFN-γ TGF-β1 were assessed before...

10.1038/s41598-020-75812-0 article EN cc-by Scientific Reports 2020-11-04

Background and Purpose Novel radiotherapy techniques increasingly use very large dose fractions. It has been argued that the biological effect of fractions may differ from conventional fraction sizes. The purpose was to study single doses. Material Methods Clonogenic cell survival MCF7 MDA-MB-231 cells determined after direct X-ray irradiation, irradiation feeder cells, or transfer conditioned medium (CM). Cell-cycle distributions apoptotic sub-G1 were measured by flow cytometry. Cytokines...

10.1371/journal.pone.0084991 article EN cc-by PLoS ONE 2014-01-22

Background REQUITE (validating pREdictive models and biomarkers of radiotherapy toxicity to reduce side effects improve QUalITy lifE in cancer survivors) is an international prospective cohort study. The purpose this project was analyse a patients recruited into using deep learning algorithm identify patient-specific features associated with the development toxicity, test approach by attempting validate previously published genetic risk factors. Methods study involved prostate treated...

10.3389/fonc.2020.541281 article EN cc-by Frontiers in Oncology 2020-10-15

Some patients with breast cancer treated by surgery and radiation therapy experience clinically significant toxicity, which may adversely affect cosmesis quality of life. There is a paucity validated clinical prediction models for toxicity. We used machine learning (ML) algorithms to develop optimise model acute desquamation after whole external beam in the prospective multicenter REQUITE cohort study.Using demographic treatment-related features (m = 122) from (n 2058) at 26 centers, we...

10.1016/j.adro.2021.100890 article EN cc-by Advances in Radiation Oncology 2022-01-04

BACKGROUND: Granulocyte–colony‐stimulating factor (G‐CSF) is known to affect functional activity and antigen expression of neutrophil granulocytes. Beside nonglycosylated filgrastim glycosylated lenograstim, pegylated (pegfilgrastim) has recently been introduced for single administration into clinical use. STUDY DESIGN AND METHODS: Here, granulocytes from 27 patients with nonmyeloid malignancies were compared functionally (migration, reactive oxygen species production, G‐CSF serum levels)...

10.1111/j.1537-2995.2007.01241.x article EN Transfusion 2007-05-22

Over-expression of epidermal growth factor receptor (EGFR) or insulin-like factor-1 (IGF-1R) have been shown to closely correlate with radioresistance breast cancer cells. This study aimed investigate the impact co-inhibition EGFR and IGF-1R on radiosensitivity two cells different profiles expression.The MCF-7 (EGFR +/-, +++) MDA-MB-468 +++, cell lines were used. Radiosensitizing effects determined by colony formation assay. Apoptosis cycle distribution measured flow cytometry. Phospho-Akt...

10.1186/1471-2407-13-297 article EN cc-by BMC Cancer 2013-06-19
Coming Soon ...